The Avanzar study could read out shortly.
ApexOnco Front Page
Recent articles
Satri-cel is filed for gastric cancer approval in China.
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
The company impresses investors, but money’s running short.
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
